Prospective study of venous thromboembolism and bleeding complications associated with primary and secondary VTE prevention during pregnancy and postpartum in women with previous VTE, hereditary thrombophilia or antiphospholipid syndrome

Prospective study of venous thromboembolism and bleeding complications associated with primary and secondary VTE prevention during pregnancy and postpartum in women with previous VTE, hereditary thrombophilia or antiphospholipid syndrome - VTE-PRO-PREG

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028688

Enrollment

1000

Registered

2022-04-05

Start date

2021-05-26

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

O22.3 D68.5

Interventions

Group 1: In women > 18 years with 1.) confirmed pregnancy and previous VTE and terminated anticoagulation, 2.) therapeutic anticoagulation because of VTE, 3.) known hereditary thrombophilia without pr

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pregnancy in the 1st/2nd trimester and previous VTE with 1. terminated or ongoing anticoagulation, 2. hereditary thrombophilia without previous VTE or 3. antiphospholipid syndrome

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Symptomatic deep vein thrombosis, superficial vein thrombosis, atypical thrombosis and/or pulmonary embolism; major bleeding according to ISTH definition	—

Secondary

Measure	Time frame
Clincial relevant non-major bleeding according to ISTH definition; arterial thrombosis, allergic skin reaction, heparin-induced thrombocytopenia, bone fractures, early and late abortions, preterm birth, praeeclampsia, eclampsia, fetal birth defect	—

Countries

Germany

Contacts

Public ContactChristina Hart

Universitätsklinikum Regensburg - Bereich Hämostaseologie

Christina.Hart@ukr.de+499419445513

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026